Theratechnologies inc.

Theratechnologies inc.

April 28, 2009 09:03 ET

Theratechnologies to Present at BioFinance 2009 Conference

MONTREAL, QUEBEC--(Marketwire - April 28, 2009) - Theratechnologies (TSX:TH) announced today that Yves Rosconi, President and Chief Executive Officer, will present an overview of the Company at the BioFinance 2009 Conference, which will take place this week in Toronto. Mr. Rosconi will be speaking at 10:30 a.m., on Wednesday, April 29.

BioFinance is the Canadian Life Science industry's leading investor conference that brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the growth hormone releasing factor. Theratechnologies recently completed two Phase 3 clinical trials evaluating tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy and signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States. With a regulatory filing to be submitted to US authorities shortly, Theratechnologies' growth strategy is firmly focused on the development and exploitation of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs.

Contact Information